Combo Treatment Doubles Survival for Patients With Advanced Kidney Cancer

heart kidney

Key Takeaways

  • Adding bevacizumab to pazopanib more than doubled survival for people with advanced kidney cancer, compared to pazopanib alone

  • Bevacizumab helps thwart cancer cell resistance to pazopanib, researchers explained

  • The study was small, so larger trials are needed

Recommended for you

Originally published on healthday.com, part of the BLOX Digital Content Exchange.

(0) comments

Welcome to the discussion.

Please log in, or sign up for a new, free account to read or post comments.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.